Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RELATIVITY-123 trial: what clinicians have said so far
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- NCT05328908 ↗
- Terminated
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on RELATIVITY-123 (nivolumab-relatlimab FDC in later-line MSS metastatic colorectal cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RELATIVITY-123 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Colorectal Neoplasms
- Interventions
- Nivolumab-relatlimab FDC; Regorafenib; TAS-102
- Arms
- Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC) · Experimental
- Arm B: Investigator's Choice · Active comparator
- Enrollment
- 769
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Apr 28, 2022
- Primary completion
- Jul 14, 2025
- Results posted
- Yes
- Registry record
- NCT05328908 · updated Aug 26, 2026